PI-02: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE

Autor: VAN DIJK M., RAB M., VAN OIRSCHOT B., BOS J., DERICHS C., RIJNEVELD A., CNOSSEN M., NUR E., BIEMOND B., BARTELS M., JANS J., VAN SOLINGE W., SCHUTGENS R., VAN WIJK R., VAN BEERS E.

Publikováno v: HemaSphere, Vol 6, Pp 09-10 (2022)

Externí odkaz: https://doaj.org/article/9d30c5fcbb2e4d92b30c722b9f7f89b3

Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome

Autor: Janssen, J J W M, Löwenberg, B, Manz, M, Biemond, B J, Westerweel, P E, Klein, S K, Fehr, M, Sinnige, H A M, Efthymiou, A, Legdeur, M C J C, Pabst, T, Gregor, M, van der Poel, M W M, Deeren, D, Tick, L W, Jongen-Lavrencic, M, van Obbergh, F, Boersma, R S, de Weerdt, O, Chalandon, Y, Heim, D, Spertini, O, van Sluis, G, Graux, C, Stüssi, G, van Norden, Y, Ossenkoppele, G J

Publikováno v: Janssen, J J W M, Löwenberg, B, Manz, M, Biemond, B J, Westerweel, P E, Klein, S K, Fehr, M, Sinnige, H A M, Efthymiou, A, Legdeur, M C J C, Pabst, T, Gregor, M, van der Poel, M W M, Deeren, D, Tick, L W, Jongen-Lavrencic, M, van Obbergh, F, Boersma, R S, de Weerdt, O, Chalandon, Y, Heim, D, Spertini, O, van Sluis, G, Graux, C, Stüssi, G, van Norden, Y & Ossenkoppele, G J 2022, ' Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome ', Leukemia, vol. 36, no. 9, pp. 2189-2195 . https://doi.org/10.1038/s41375-022-01657-3
Leukemia, 36(9), 2189-2195. Nature Publishing Group
Leukemia, Vol. 36, no.9, p. 2189-2195 (2022)
Leukemia, 36, 2189-2195. Nature Publishing Group

Treatment results of AML in elderly patients are unsatisfactory. In an open label randomized phase II study, we investigated whether addition of the XPO1 inhibitor selinexor to intensive chemotherapy would improve outcome in this population. 102 AML

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::287a701a807a9162ad042541d5d386bd
http://www.scopus.com/inward/record.url?scp=85134692962&partnerID=8YFLogxK

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tolérance et efficacité de voxelotor sur une période de plus de 4 ans chez les patients atteints de drépanocytose : résultats actualisés d’une étude d’extension en ouvert de l’essai de phase 3 HOPE

Autor: Achebe, M., Hassab, H., Al-Kindi, S., Brown, C., Telfer, P., Biemond, B., Lipato, T., Davis, M., Gray, S., Alfa Cissé, O., Gordeuk, V.

Publikováno v: In La revue de médecine interne June 2024 45 Supplement 1:A130-A131